NGM·Healthcare·$802M·#68 / 520 in Healthcare
ESPR Esperion Therapeutics, Inc.
69SOLID
CATEGORY BREAKDOWN
GROWTH34
QUALITY88
STABILITY100
VALUATION95
GOVERNANCE4
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+21.3%
34
> 50% strong
Gross Margin
Revenue retained after direct costs
67.9%
97
> 50% strong
Cash Runway
Months of cash at current burn rate
154 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-83.5%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.0x
95
< 3x strong
Rule of 40
Growth rate plus operating margin
36
74
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.7%
5
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+29.6%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ESPR WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when ESPR's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.